The latest Haydn Kissick lab paper is out! I am delighted to have worked w/ my mentor, friend, and role model Jennifer Carlisle as co-first authors to share our latest work in @JITC, detailing features of patients' peripheral and intratumoral response to #ICB in #RCC.

.@TheNCI recently awarded more than $7.9 million to support a new Radiation Oncology-Biology Integration Network (ROBIN) center at Winship Cancer Institute of Emory University and the Cleveland Clinic. #radonc ➡️ fal.cn/3spc9

We are hiring a Bioinformatician. Experience in immunology is a plus. Please see the link below if interested. Feel free to DM me with any questions or inquiries. nam11.safelinks.protection.outlook.com/?url=https%3A%…

Really excited to share the work I have done with Haydn Kissick over my PhD! In this work we show that CD8 T cell activation and differentiation in cancer happens in two distinct phases. Tweet-orial below summarizes the main findings we have described. cell.com/immunity/fullt…

Fascinating new pre-clinical paper showing how time-of-day can influence the anti-tumor immune response. nature.com/articles/d4158…. Data is accumulating in support of our Lancet Onc study: thelancet.com/journals/lanon…

Check out our new preprint on the immune architecture in brain mets and the impact of pre-op SRS. Carey Jansen, MD PhD Haydn Kissick researchsquare.com/article/rs-272…

Very excited to share our new preprint detailing a fun collaboration between Zach Buchwald MD PhD & Haydn Kissick and discussing TCF1+ stem-like cells/immune niches in brain mets and how they are affected by exposure to radiation therapy -- check it out on Research Square Preprints!

Interested in a immunology faculty position at a stellar place Emory University with amazing collaborators? Look no further! Apply to this link: nature.com/naturecareers/…

New #JITC article: Impact of immunotherapy time-of-day infusion on survival & immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis bit.ly/3IVUE4P Carey Jansen, MD PhD Mehmet Asim Bilen,MD Mohammad K. Khan, MD Haydn Kissick Zach Buchwald MD PhD David Qian, MD, PhD

A 2022 Science Immunology Review highlights the benefits of morning vaccination compared with afternoon/evening vaccination in humans. Learn more on #DayOfImmunology: scim.ag/6LH

Plz check out our new paper on pre-op SRS and the immune microenvironment of human brain metastases. nature.com/articles/s4146… Big team effort: Carey Jansen, MD PhD Meghana Pagadala MD PhD Haydn Kissick Maria Andrea Cardenas Mohammad K. Khan, MD and many more.

Our publication on pre-op SRS and the immune microenvironment of human brain metastases (BrM) is finally online at Nature Communications! This one was a journey from inception to publication, so we're excited to share. See below for highlights! nature.com/articles/s4146…

I am so excited to share my first author publication, “Differentiation fate of a stem-like CD4 T cell control immunity to cancer” published today in @nature, detailing the project I’ve been working on in Haydn Kissick’s lab. tinyurl.com/33d24k89

New #JITC review: Impact of race, ethnicity, and social determinants on outcomes following immune checkpoint therapy bit.ly/4e7wRft Rahul Nayak Meili Aiello Zach Buchwald MD PhD Andres Chang, MD, PhD

I have exciting news!🌟 In Jan 2025, I will begin my position as an Assistant Professor at UTHealth Houston School of Public Health in the Center for Human Genetics & Department of Epidemiology :) I'm hiring at all levels, so please send your trainees my way!! More info at heylab.org 🧬

Maria Andrea Cardenas talk is now on YouTube! 📣 Differentiation fate of a stem-like CD4 T cells control immunity to Cancer Haydn Kissick lab Emory School of Medicine youtu.be/rC69rAz6OeE

Our new paper is now available online. nature.com/articles/s4146…

Winship radiation oncologist Zachary Buchwald, MD, PhD, provides a brief description of a fascinating clinical trial evaluating how time-of-day–specified immunotherapy for patients with advanced melanoma affects their outcome. #ASCO25

🕒 First phase 3 RCT on time-of-day of immunochemotherapy in stage IIIC–IV #NSCLC (N=210) ✅ Non-invasive, cost-free intervention ✅ Consistent benefit across subgroups ✅ Immune biomarker correlation (CD8⁺↑) ✍️ Awaiting peer-reviewed publication Zhang et al.

Excited to share our study of RT + IAP antagonist tolinapant in cis-ineligible HNSCC, showing safety/feasibility and promising LRC …rjournals-org.proxy.library.emory.edu/clincancerres/… Bill Stokes Nabil Saba, MD James Bates